Cantor Fitzgerald reiterates Rocket Lab stock rating on Mynaric deal By Investing.com - ca.investing.com

Rocket Lab received German regulatory approval to acquire Mynaric for approximately $75M (expected to close in April) and secured a $190M U.S. DoD contract for 20 HASTE launches, boosting its backlog to ~70 launches. The company reported a ~$1.85B backlog (management expects ~37% to be recognized within 12 months), LTM revenue of $601.8M and a market cap of $38.6B; shares are up ~313% over the past year. Cantor Fitzgerald reiterated an Overweight and Stifel maintained a Buy with a $90 target, supporting positive sentiment despite InvestingPro flagging the stock as overvalued.

Analysis

Regulatory clearance for a Europe-headquartered optics supplier materially lowers a non-obvious barrier: prime contractors and defense buyers that require European-origin hardware just gained a single-vendor path to system-level procurement. That creates a near-term opportunity for the acquirer to win follow-on integration work (higher margin, recurring service/upgrade revenue) but also moves the company from a launch-centric vendor to a systems integrator with very different margin and working-capital dynamics.

Technical integration is the limiting reagent. Space-grade laser comms require flight qualification, thermal/vibration cycling, and in-orbit demonstrations—mileposts that typically stretch 6–18 months and produce lumpy, milestone-tied cash flows. That timeline implies revenue upside is back-loaded and sensitive to single-event failures; supply-chain constraints on optical components and specialized optics spares will amplify any schedule slips.

Market pricing already bakes in a successful, on-time conversion of system wins into steady revenue; this narrows the upside and raises asymmetric downside if vehicle cadence or program milestones slip. The sector is vulnerable to a re-rating should a larger player IPO or reveal unit economics that compress multiples—monitor implied volatility and milestone calendars, and size positions to the single-failure risk profile.

Key Decisions for Investors

• RKLB — Tactical, growth-biased: Buy a 9–12 month call spread (long near-term-dated call, sell a higher strike farther-out) sized at 1–2% NAV. Rationale: asymmetric upside if integration and launch cadence stay on track; R/R: target 2.0–3.0x premium, max loss = premium paid.
• RKLB — Insurance hedge: Buy 6–9 month puts (25–30% OTM) sized 0.5–1% NAV to protect against a milestone delay or launch failure. Rationale: protects portfolio tail exposure from a single-event technical setback; payoff concentrates in a 30–50% equity drawdown scenario.
• Pair trade — Long LHX/RTX 12–24 month (1–1.5% NAV) vs short RKLB 6–12 month (0.5–1% NAV): Capture relative safety/scale of primes who win integration work while shorting execution/valuation risk at the acquisitive company. R/R: target 20–35% relative outperformance; risk is sector-wide re-rating or prime execution failures.
• Volatility carry: Sell near-term (30–60 day) OTM RKLB calls to fund part of the long-dated call spread or to generate income, limiting naked short exposure to a small notional (<=0.5% NAV). Rationale: near-term catalysts often already priced; collect time decay while maintaining long-dated upside. Risk: gap higher on surprise positive news—cap loss with buy-back or conversion to a collar.